Otenabant (CP-945,598) is a drug that acts as a potent and highly selective CB1 antagonist.

[1] It was developed by Pfizer for the treatment of obesity,[2] but development for this application has been discontinued following the problems seen during clinical use of the similar drug rimonabant.

[3]

This cannabinoid related article is a stub.

You can help Wikipedia by expanding it.